Trial | N | Target | Costimu-latory domain | CR (%) | Overall survival rate | CRS and ICANS grading criteria | CRS (%) | Severe CRS* (%) | ICANS (%) | Severe ICANS* (%) | Toxicity related mortality | Refs |
---|---|---|---|---|---|---|---|---|---|---|---|---|
ALL | ||||||||||||
 Maude et al. 2014 | 30 | CD19 | 4-1BB | 27(90) | 78% (6 m) | CTCAE†| 30(100) | 8(27) | 13(43) | NR | 0 | [31] |
 Lee et al. 2015 | 20 | CD19 | CD28 | 14(70) | 50% (12 m) | CTCAE†| 16(80) | 6(30) | 6(30) | 1(5) | 0 | [30] |
 Turtle et al. 2016 | 30 | CD19 | 4-1BB | 27(93) | NR | CTCAE†| 25(83) | 7(23) | 15(50) | 15(50) | 1 CRS 1 ICANS | [84] |
 Gardner et al. 2017 | 43 | CD19 | 4-1BB | 40(93) | 69.5% (12 m) | CTCAE†| 40(93) | 10(23) | 21(49) | 9(21) | 0 | [205] |
 Maude et al. 2018 | 75 | CD19 | 4-1BB | 61(81) | 76% (12 m) | PENN/CHOP CTCAE | 58(77)P | 35(46) | 30(40)C | 10(13) | 1 ICANS | [206] |
 Park et al. 2018 | 53 | CD19 | CD28 | 44(83) | 50% (12.9 m) | MSKCC CTCAE | 45(85)M | 14(26) | 23(44)C | 22(42) | 1 CRS | [117] |
 Frey et al. 2020 | 35 | CD19 | 4-1BB | 24(69) | 50% (19.1 m) | PENN/CHOP CTCAE | 33(94)P | 6(17) | 14(40)C | 2(6) | 3 CRS | [109] |
 Fry et al. 2018 | 21 | CD22 | 4-1BB | 12(57) | NR | CTCAE†| 16(76) | 0(0) | 6(28) | 0(0) | 0 | [80] |
 Shah et al. 2020 | 58 | CD22 | 4-1BB | 40(70) | 50% (13.4 m) | Lee CTCAE ASTCT | 50(86)L | 5(10)L 12(24)A | 19(33)C | 1(2) | 0 | [81] |
NHL | ||||||||||||
 Turtle et al. 2016 | 32 | CD19 | 4-1BB | 11(34) | ‡ | CTCAE†| 20(63) | 4(13) | 9(28) | 9(28) | 1 ICANS | [85] |
 Schuster et al. 2017 | 28 | CD19 | 4-1BB | 16(57) | 57% (28.6 m)§ | PENN/CHOP CTCAE | 16(57)P | 5(18) | 11(39)C | 3(11) | 1 ICANS | [87] |
 Neelapu et al. 2017 | 101 | CD19 | CD28 | 55(54) | 52% (18 m) | Lee CTCAE | 94(93)L | 13(13) | 65(64)C | 28(28) | 2 CRS | [89] |
 Schuster et al. 2019 | 111 | CD19 | 4-1BB | 37(40) | 50% (12 m) | PENN/CHOP CTCAE | 64(58)P | 24(22) | 23(21)C | 13(12) | 0 | [118] |
 Abramson et al. 2020 | 269 | CD19 | 4-1BB | 136(53) | 58% (12 m) | Lee CTCAE | 113(42)L | 6(2) | 80(30)C | 27(10) | 0 | [207] |
MCL | ||||||||||||
 Wang et al. 2020 | 68 | CD19 | CD28 | 40(67) | 83% (12 m) | Lee CTCAE | 62(91)L | 10(15) | 43(63)C | 21(31) | 0 | [208] |
MM | ||||||||||||
 Brudno et al. 2018 | 16 | BCMA | CD28 | 10(63) | 50% (7.1 m)¶ | Lee | 15(94)L | 6(38) | NR | NR | NR | [209] |
 Zhao et al. 2018 | 57 | BCMA | 4-1BB | 39(68) | 50% (15 m)§ | Lee CTCAE | 51(90)L | 4(7) | 1(2)C | 0(0) | NR | [210] |
 Cohen et al. 2019 | 25 | BCMA | 4-1BB | 2(8) | 50% (502d) | PENN/CHOP CTCAE | 22(88)P | 8(32) | 8(32)C | 3(12) | 0 | [211] |
 Raje et al. 2019 | 33 | BCMA | 4-1BB | 15(45) | 50% (11.8 m)§ | Lee CTCAE | 25(76)L | 2(6) | 14(42)C | 1(3) | 0 | [212] |
 Munshi et al. 2021 | 128 | BCMA | 4-1BB | 42(33) | 78% (12 m) | Lee CTCAE | 107(84)L | 7(5) | 23(18)C | 4(3) | 1 CRS | [213] |
CLL | ||||||||||||
 Porter et al. 2015 | 14 | CD19 | 4-1BB | 4(29) | 50% (29 m) | CTCAE†| 9(64) | 6(43) | 6(43) | 1(7) | 0 | [214] |
 Turtle et al. 2017 | 24 | CD19 | 4-1BB | 4(21) | 50% (6.6 m) | Lee CTCAE†| 20(83)L | 2(8) | 8(33)C†| 6(25) | 1 CRS and ICANS | [86] |
 Frey et al. 2020 | 38 | CD19 | 4-1BB | 9(28) | 50% (64 m) | PENN/CHOP CTCAE ASTCT | 24(63)P 23(59)A | 9(24) 4(11) | 3(8)C | 0(0) | 0 | [215] |